We have shown that PACAP is closely related to disease burden, as our results indicate that patients with active disease, higher plasma cell infiltration in bone marrow, higher tumor markers (LDH, B2M, BJ protein), and higher ISS stage have lower PACAP levels. This evidence concerns the gene B2M and neoplasm.